Posaconazole, a derivative of itraconazole, is a second-generation triazole antifungal agent approved by the FDA in 2006. It is indicated for the treatment of candidemia caused by Candidaspp. and cryptococcosis caused by Cryptococcusspp., as well as fungal infections affecting the respiratory tract, gastrointestinal tract, urinary tract, peritoneum, and meninges.

AccuSift provides high-performance competitive antibody pairs for posaconazole detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 0.2 μg/mL